Rameda Pharmaceuticals
Hoda Mayhoub is an experienced professional with a diverse background in internal communications, employee engagement, and human resources. Currently serving as the Internal Communications & Benefits Head at Rameda Pharmaceuticals since January 2016, Hoda has successfully developed strategic communication plans and managed internal events. Previous roles include HR Business Partner, HR Supervisor, and HR Specialist, where responsibilities encompassed performance management, recruitment, and employee relations. Hoda also held positions such as Cyber Security Analyst at ITX Management Consulting and Executive Manager at Esma3 Kittab, showcasing a blend of HR and managerial expertise. Hoda's educational qualifications include a Human Resource Management Certificate from The American University in Cairo and a Bachelor of Arts in Languages and Translation from Al-Azhar University, with ongoing MBA studies at the Arab Academy for Science, Technology and Maritime Transport.
This person is not in the org chart
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.